Table 2.
Study outcomes by study day and treatment groups.
| Condition |
||
|---|---|---|
| Outcome variable: study time-point | Experimental (n = 56) | Placebo (n = 55) |
| Mean proportion methadone-negative urine testsa (SD) | ||
| Day 23: end of infusion phase | 0.5 (0.4) | 0.5 (0.4) |
| Day 40: end of medication phase | 0.4 (0.4) | 0.5 (0.4) |
| Day 108: end of study | 0.3 (0.3) | 0.4 (0.3) |
| Craving (mean, SD)b | ||
| Day 23: end of infusion phase | 2.8 (2.9) | 2.9 (3.0) |
| Day 40: end of medication phase | 3.1 (3.4) | 2.9 (3.2) |
| Day 108: end of study | 2.2 (2.7) | 2.4 (3.4) |
| % 3 consecutive negative UA tests (n) | ||
| Day 40: end of medication phase | 35.7 (20) | 45.5 (25) |
| Day 108: end of study | 39.3 (22) | 50.9 (28) |
| % retained in study (n) | ||
| Day 23: end of infusion phase | 82.1 (46) | 85.5 (47) |
| Day 40: end of medication phase | 53.6 (30) | 76.4 (42) |
| Day 108: end of study | 32.1 (18) | 47.3 (26) |
a
Total of urine tests possible: three for in-patient sites and six for out-patient site to end of infusion phase, five for in-patient sites and eight for out-patient site to end of medication phase, and 15 for in-patient sites and 18 for out-patient sites to end of study.
b
The craving score was computed from three items with Likert scale responses from 0–4, with a possible total score ranging from 0 to 12.
SD: standard deviation; UA: urinalysis.